top of page
Picture4.png

Thomas Malcolm Ph.D. CSIO Caravan Biologix

Malcolm Kermode Headshot BW HR_edited_edited.png

Dr. Malcolm brings 25 years of combined experience in genetic regulation of virally infected human cells and human cancers,  gene editing of infectious diseases, chimeric antigen receptor therapeutic development, targeted delivery of therapeutic biomolecules and extracellular vesicle science to the executive team of Caravan Biologix Inc. Dr. Malcolm founded Caravan Biologix to develop the novel mini-CAR™ BioNV technology to resolve the challenges associated with CAR cell therapies in treating solid tumor cancers as well as the delivery of biologic therapeutics to treat an abundance of human diseases.

Dr. Malcolm also serves as the COO and Board Member for Kermode Biotechnologies Inc., a multinational company that he co-founded in 2019 that is dedicated to developing vaccines and therapeutics for protecting and treating livestock animals from the economically devastating African Swine Fever Virus and Swine Influenza Virus.

 

Prior to these roles, Dr. Malcolm served as a Founder, CEO and CSO of Excision Biotherapeutics Inc. from 2015 to 2019 where he completed a $10+ M series round of funding and positioned the Company for success with critical CRISPR gene editing licenses from UC Berkeley.

In addition to his executive roles, Thomas serves on the U.S. Board of Directors for Emergex Vaccines Inc., a U.K. based company developing novel immunomodulatory vaccines for infectious diseases. Thomas is also an Advisor to Cila Therapeutics Inc., located in Boston MA, a company developing inhaled therapies for the treatment of a rare genetic disorder, Primary Ciliary Dyskinesia (PCD) and late stage Sars-Cov-2 hydrofluidic lung infections. Furthermore, Dr. Malcolm serves on the advisory board of Ferghana Partners, a biotechnology brokerage firm located in New York City. 

Dr. Malcolm founded Criterion BioScience Research Group in 2012, a life sciences advisory group looking at emergent biotechnologies. From 2015 to late 2018, he also served as CSO for Biomark Diagnostics, a company developing metabolomic diagnostics in Vancouver, Canada.  

Dr. Malcolm has published his work on viruses and cancers in multiple high impact journals. He is also an inventor on numerous patents. Thomas earned his Ph.D. in Biochemistry and Molecular Biology from the University of British Columbia, Vancouver, Canada and continued his studies as a postdoctoral fellow at Sloan Kettering Memorial Cancer Center and Mount Sinai School of Medicine in New York, NY.

bottom of page